What mattered for Lucence Diagnostics’ journey, above any specific business strategy, was simply the will to take something commercial, right to the patient.
The firm’s growing revenue and the uptake of its tests are validations of its technology.
Says chief executive Tan Min-Han: “A technology that is sitting in the lab, that is not taken out and scaled up, is of obviously very different value (to patients) from one that has been taken out and scaled up.”
(Source: Reproduced with permission from The Business Times © Singapore Press Holdings Limited. Permission required for reproduction.)